Association of HER2DX with pathological complete response and survival outcomes in HER2-positive breast cancer


Background: The HER2DX genomic test predicts pathological complete response (pCR) and survival outcome in early-stage HER2-positive (HER2+) breast cancer. Here, we evaluated the association of HER2DX scores with (i) pCR according to hormone receptor status and various treatment regimens, and (ii) survival outcome according to pCR status.

Materials and methods: Seven neoadjuvant cohorts with HER2DX and clinical individual patient data were evaluated (DAPHNe, GOM-HUGUM-2018-05, CALGB-40601, ISPY-2, BIOOnHER, NEOHER and PAMELA). All patients were treated with neoadjuvant trastuzumab (n = 765) in combination with pertuzumab (n = 328), lapatinib (n = 187) or without a second anti-HER2 drug (n = 250). Event-free survival (EFS) and overall survival (OS) outcomes were available in a combined series of 268 patients (i.e. NEOHER and PAMELA) with a pCR (n = 118) and without a pCR (n = 150). Cox models were adjusted to evaluate whether HER2DX can identify patients with low or high risk beyond pCR status.

Results: HER2DX pCR score was significantly associated with pCR in all patients [odds ratio (OR) per 10-unit increase = 1.59, 95% confidence interval 1.43-1.77; area under the ROC curve = 0.75], with or without dual HER2 blockade. A statistically significant increase in pCR rate due to dual HER2 blockade over trastuzumab-only was observed in HER2DX pCR-high tumors treated with chemotherapy (OR = 2.36 (1.09-5.42). A statistically significant increase in pCR rate due to multi-agent chemotherapy over a single taxane was observed in HER2DX pCR-medium tumors treated with dual HER2 blockade (OR = 3.11, 1.54-6.49). The pCR rates in HER2DX pCR-low tumors were ≤30.0% regardless of treatment administered. After adjusting by pCR status, patients identified as HER2DX low-risk had better EFS (P < 0.001) and OS (P = 0.006) compared with patients with HER2DX high-risk.

Conclusions: HER2DX pCR score and risk score might help identify ideal candidates to receive neoadjuvant dual HER2 blockade in combination with a single taxane in early-stage HER2+ breast cancer.

Key words: HER2, breast cancer, HER2DX, pertuzumab, pathological complete response, neoadjuvant
INTRODUCTION

Neoadjuvant systemic therapy is standard for patients with clinical stage II-III HER2-positive (HER2+) breast cancer according to the 7th edition of the American Joint Committee on Cancer (AJCC) staging system. The pathological complete response (pCR) rates are 29%-46% following trastuzumab in combination with chemotherapy. The addition of a second anti-HER2 agent, such as pertuzumab or lapatinib, to trastuzumab and chemotherapy increases pCR rates by 10%-20%, albeit with modest improvements in long-term survival. Nonetheless, patients with HER2+ disease who experience a pCR have better long-term survival outcomes than those without a pCR. This observation seems valid irrespective of the type of systemic therapy received before surgery.

Several clinical questions remain unanswered regarding the optimal neoadjuvant treatment approach in HER2+ breast cancer. For example, who benefits from pertuzumab when added to trastuzumab and chemotherapy is still unclear. In addition, it is unclear as to what the optimal chemotherapy backbone in combination with dual HER2 blockade is. The DAPHNe phase II trial treated 98 patients with stage II-III HER2+ disease with 3 months of paclitaxel, trastuzumab and pertuzumab (THP), with no further chemotherapy in 98% of patients who achieved a pCR. This observation seems valid irrespective of the type of systemic therapy received before surgery.

In patients who do not achieve a pCR, adjuvant trastuzumab emtansine (T-DM1) improves invasive disease-free survival compared to trastuzumab; thus, pCR is a highly clinically meaningful endpoint for multiple reasons.

Here, we combined HER2DX and clinical data from the ISPY-2, CALGB-40601, DAPHNe, GOM, BioOnHER, NEOHER and PAMELA cohorts to test the ability of the HER2DX pCR score to predict pCR across different subgroups of patients. Specifically, we focused on two clinically relevant questions: who benefits from the addition of a second anti-HER2 agent, pertuzumab or lapatinib, as dual therapy with trastuzumab and chemotherapy, and who benefits from multi-agent chemotherapy over a single-agent taxane when treated with dual HER2 blockade. Finally, we tested the ability of the HER2DX risk score to predict survival outcome according to pCR status in a combined dataset (i.e. NEOHER and PAMELA) with long-term follow-up.

MATERIALS AND METHODS

ISPY-2 cohort

The ISPY-2 phase II trial was an adaptive trial that randomized 128 patients with clinical stage II-III HER2+ breast cancer to four cycles of T-DM1 [3.6 mg/kg intravenously (i.v.) every 3 weeks] in combination with pertuzumab (n = 52) or THP (n = 45), or a common control arm of weekly paclitaxel (80 mg/m²) and trastuzumab for 12 weeks (n = 31). All patients received four cycles of doxorubicin (60 mg/m²) and cyclophosphamide (600 mg/m²) i.v., every 2-3 weeks, before surgery (Supplementary Figure S1, available at https://doi.org/10.1016/j.jannonc.2023.05.012). The results of the HER2DX assay in ISPY-2 have been previously reported in 127 patients (99.2%).

CALGB-40601 cohort

The CALGB-40601 study is a phase III clinical trial that randomized 305 women with untreated stage II and III HER2+ breast cancer to receive weekly paclitaxel (80 mg/m²) for 16 weeks combined with trastuzumab plus 1000 mg/day of lapatinib (THL), trastuzumab (TH) or lapatinib (TL) (Supplementary Figure S1, available at https://doi.org/10.1016/j.jannonc.2023.05.012). The results of the HER2DX assay are available in 263 patients (86.2%).

DAPHNe cohort

DAPHNe is a prospective investigator-initiated, single-arm phase II study, where 98 patients were assigned to receive preoperative paclitaxel (80 mg/m² weekly for 12 weeks) in combination with THP (Supplementary Figure S1, available at https://doi.org/10.1016/j.jannonc.2023.05.012). The HER2DX results for 80 patients (81.6%) in DAPHNe are reported elsewhere.

GOM cohort

GOM is an ongoing retrospective observational study since 2018 of consecutive patients with newly diagnosed stage I-III HER2+ breast cancer who were candidates for neoadjuvant therapy across seven public hospitals in Spain. All patients received six cycles of docetaxel 75 mg/m² i.v. every 3 weeks in combination with carboplatin area under the
ROG curve (AUC) of 6 i.v. every 3 weeks and trastuzumab every 3 weeks (TCH). Once neoadjuvant pertuzumab was reimbursed in Spain, most patients received TCH in combination with pertuzumab 840 mg i.v. loading dose, followed by pertuzumab every 3 weeks (TCHP) depending on high-risk tumors at the clinician’s discretion and/or according to the hospital’s criteria for availability of the drug (Supplementary Figure S1, available at https://doi.org/10.1016/j.annonc.2023.05.012). The results of the HER2DX assay are available in 155 patients and are reported elsewhere.19

**BiOnHER cohort**

BiOnHER is a single-arm phase II trial carried out at the Catalan Institute of Oncology (Barcelona, Spain), where 46 patients with clinical stage II-III HER2+ were treated with one cycle of trastuzumab and pertuzumab without chemotherapy, followed by weekly paclitaxel for 16 weeks in combination with trastuzumab and pertuzumab every 3 weeks (THP) (Supplementary Figure S1, available at https://doi.org/10.1016/j.annonc.2023.05.012). The results of the HER2DX assay are available in all patients.

**PAMELA cohort**

SOLTI-1114 PAMELA was an open-label, single-group, phase II trial of 151 patients with HER2+ breast cancer, stage I-IIIA and a performance status of 0-1. Patients were given lapatinib (1000 mg per day) and trastuzumab for 18 weeks; hormone receptor (HR)-positive patients were additionally given letrozole (2.5 mg/day) or tamoxifen (20 mg/day) according to menopausal status (Supplementary Figure S1, available at https://doi.org/10.1016/j.annonc.2023.05.012). Treatment after surgery was left to the treating physician’s discretion. The results of the HER2DX assay are available in 84 patients (55.6%) and are reported elsewhere.18,19 For this analysis, the median follow-up was 6.4 years.

**NEOHER cohort**

NEOHER is based on two retrospective cohorts from the Hospital Clinic of Barcelona and Padova University. Patients with early-stage HER2+ breast cancer and a performance status of 0-1 were treated, as per standard practice, with neoadjuvant trastuzumab-based chemotherapy for 3-6 months, followed by surgery (Supplementary Figure S1, available at https://doi.org/10.1016/j.annonc.2023.05.012). Adjuvant treatment was completed with trastuzumab for up to 1 year, and a minimum of 5 years of hormonal therapy for patients with HR-positive tumors. Only 14 patients with residual disease at surgery received adjuvant T-DM1. Radiation therapy was administered according to local guidelines. The results of the HER2DX assay are available in 184 patients and are reported elsewhere.18 For this analysis, the median follow-up was 5.9 years.

**TCGA dataset**

Clinical, genetic (i.e. somatic mutations), genomic (i.e. gene expression) and proteomic data from the breast cancer The Cancer Genome Atlas (TCGA) dataset was obtained from cbioportal.13 HER2DX pCR score was applied on to RNA-seq data of 161 HER2+ tumors.

**HER2DX assay**

HER2DX was evaluated in tumor samples from pre-treatment baseline samples. In the GOM, BiOnHER, NEOHER, PAMELA and DAPHNe cohorts, the HER2DX standardized assay was carried out using RNA extracted from formalin-fixed, paraffin-embedded (FFPE) tissue, as previously described.16,18,19 In ISPY-2 and CALGB-40601, HER2DX was applied on to publicly available microarray data (GSE181574) and mRNAseq data, respectively (dbGaP website, under accession number phs001570.v3.p1), as previously described.16 From FFPE RNA, the HER2DX standardized assay was carried out on the nCounter platform (NanoString Technologies, Seattle, WA). The HER2DX assay is based on four different gene signatures comprising 27 genes, including the 14-gene immunoglobulin (IGG) module (i.e. CD27, CD79A, HLA-C, IGJ, IGKC, IGL, IGLV3-25, IL2RG, CXCL8, LAX1,NTN3, PIK3, POU2AF1 and TNFRSF17). The other three gene signatures were: a four-gene tumor cell proliferation signature (EXO1, ASPM, NEK2 and KIF23), a five-gene luminal differentiation signature (BCL2, DNAJC12, AGR3, AFF3 and ESR2) and the four-gene HER2 amplicon signature (ERBB2, GRB7, STARD3 and TAP).16 Two scores were calculated for each patient: (i) HER2DX PCR score and (ii) HER2DX risk score (both from 0 to 100). Pre-established cut-offs were used to create HER2DX pCR groups [low (0-33.3), medium (33.3-66.7) and high (66.7-100)], and also to create HER2DX risk groups [low (0-50) and high (50-100)].16

**Statistical analyses**

The first objective was to evaluate the association of the HER2DX pCR score with pCR status. Univariable and multivariable logistic regression models were used to investigate the association for each variable with pCR in terms of odds ratios (ORs) with 95% confidence interval (95% CI). All variables evaluated in the univariable analysis were included in the multivariable model. The first multivariable analysis used multiple imputation of random missing values using the mice R package (Supplementary Table S1, available at https://doi.org/10.1016/j.annonc.2023.05.012). Additionally, two sensitivity analyses were carried out: (i) without data imputation and (ii) excluding data from the CALGB-40601, ISPY-2, NEOHER and PAMELA cohorts because they were included in the original HER2DX validation. The association of the HER2DX pCR score with pCR was also evaluated in several clinically relevant subgroups of patients: (i) patients treated with chemotherapy and trastuzumab, (ii) patients treated with chemotherapy and dual HER2 blockade, (iii) patients treated only with dual HER2 blockade, (iv) patients with HR-positive disease and (v) patients with HR-negative disease. To summarize the overall
Table 1. Clinical—pathological characteristics of the seven neoadjuvant cohorts evaluated

<table>
<thead>
<tr>
<th>Clinicopathological features</th>
<th>Overall (n = 765)</th>
<th>CALGB-40601 (n = 206)</th>
<th>ISPY-2 (n = 127)</th>
<th>DAPHNe (n = 80)</th>
<th>GOM (n = 155)</th>
<th>BIOnHER (n = 46)</th>
<th>NEOHER (n = 67)</th>
<th>PAMELA (n = 84)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (mean and range), years</td>
<td>52 (22-86)</td>
<td>49 (24-75)</td>
<td>NA</td>
<td>50 (26-78)</td>
<td>50 (22-74)</td>
<td>60 (35-83)</td>
<td>54 (34-81)</td>
<td>56 (30-86)</td>
</tr>
<tr>
<td>Clinical tumor stage, n (%)</td>
<td>T1</td>
<td>132 (21.2)</td>
<td>16 (8.4)</td>
<td>NA</td>
<td>15 (18.8)</td>
<td>35 (22.6)</td>
<td>14 (30.4)</td>
<td>13 (19.4)</td>
</tr>
<tr>
<td>Clinical tumor stage, n (%)</td>
<td>T2-T3-T4</td>
<td>491 (78.8)</td>
<td>175 (91.6)</td>
<td>NA</td>
<td>65 (81.2)</td>
<td>120 (77.4)</td>
<td>32 (69.6)</td>
<td>54 (80.6)</td>
</tr>
<tr>
<td>Clinical nodal stage, n (%)</td>
<td>NO</td>
<td>231 (35.5)</td>
<td>NA</td>
<td>NA</td>
<td>52 (65.0)</td>
<td>56 (36.1)</td>
<td>27 (58.7)</td>
<td>42 (62.7)</td>
</tr>
<tr>
<td>Clinical nodal stage, n (%)</td>
<td>N1-N2-N3</td>
<td>201 (46.5)</td>
<td>NA</td>
<td>NA</td>
<td>28 (35.0)</td>
<td>99 (63.9)</td>
<td>19 (41.3)</td>
<td>25 (37.3)</td>
</tr>
<tr>
<td>Hormone receptor, n (%)</td>
<td>Negative</td>
<td>277 (36.3)</td>
<td>84 (41.0)</td>
<td>44 (34.6)</td>
<td>23 (29.1)</td>
<td>50 (32.3)</td>
<td>15 (32.6)</td>
<td>18 (26.9)</td>
</tr>
<tr>
<td>Hormone receptor, n (%)</td>
<td>Positive</td>
<td>468 (63.7)</td>
<td>121 (59.0)</td>
<td>83 (65.4)</td>
<td>56 (70.9)</td>
<td>105 (67.7)</td>
<td>31 (67.4)</td>
<td>49 (73.1)</td>
</tr>
<tr>
<td>PAM50, n (%)</td>
<td>Basal-like</td>
<td>82 (10.8)</td>
<td>32 (15.5)</td>
<td>27 (21.3)</td>
<td>5 (6.2)</td>
<td>8 (5.2)</td>
<td>1 (2.4)</td>
<td>2 (3.0)</td>
</tr>
<tr>
<td>PAM50, n (%)</td>
<td>HER2-E</td>
<td>316 (41.6)</td>
<td>46 (22.3)</td>
<td>28 (22.0)</td>
<td>46 (57.5)</td>
<td>80 (51.6)</td>
<td>26 (63.4)</td>
<td>33 (49.3)</td>
</tr>
<tr>
<td>PAM50, n (%)</td>
<td>HER2-F</td>
<td>66 (8.6)</td>
<td>0 (0)</td>
<td>31 (24.4)</td>
<td>0 (0)</td>
<td>0 (0)</td>
<td>0 (0)</td>
<td>0 (0)</td>
</tr>
<tr>
<td>PAM50, n (%)</td>
<td>HER2-F</td>
<td>84 (11.0)</td>
<td>0 (0)</td>
<td>44 (34.6)</td>
<td>0 (0)</td>
<td>0 (0)</td>
<td>0 (0)</td>
<td>17 (25.4)</td>
</tr>
<tr>
<td>PAM50, n (%)</td>
<td>TCH</td>
<td>69 (9.0)</td>
<td>0 (0)</td>
<td>0 (0)</td>
<td>67 (43.2)</td>
<td>0 (0)</td>
<td>2 (3.0)</td>
<td>0 (0)</td>
</tr>
<tr>
<td>PAM50, n (%)</td>
<td>THP</td>
<td>89 (11.6)</td>
<td>0 (0)</td>
<td>0 (0)</td>
<td>88 (56.8)</td>
<td>0 (0)</td>
<td>1 (1.5)</td>
<td>0 (0)</td>
</tr>
<tr>
<td>PAM50, n (%)</td>
<td>THL</td>
<td>103 (13.5)</td>
<td>0 (0)</td>
<td>0 (0)</td>
<td>46 (100)</td>
<td>0 (0)</td>
<td>0 (0)</td>
<td>0 (0)</td>
</tr>
<tr>
<td>PAM50, n (%)</td>
<td>THP</td>
<td>126 (16.5)</td>
<td>0 (0)</td>
<td>0 (0)</td>
<td>80 (100)</td>
<td>0 (0)</td>
<td>0 (0)</td>
<td>0 (0)</td>
</tr>
<tr>
<td>Cytotoxic therapy and HER2 blockade, n (%)</td>
<td>Single CT and trastuzumab</td>
<td>115 (15.0)</td>
<td>103 (50.0)</td>
<td>0 (0)</td>
<td>0 (0)</td>
<td>3 (0.0)</td>
<td>0 (0)</td>
<td>12 (17.9)</td>
</tr>
<tr>
<td>Cytotoxic therapy and HER2 blockade, n (%)</td>
<td>Single CT and dual blockade</td>
<td>229 (29.9)</td>
<td>103 (50.0)</td>
<td>0 (0)</td>
<td>80 (100)</td>
<td>0 (0)</td>
<td>46 (100)</td>
<td>0 (0)</td>
</tr>
<tr>
<td>Cytotoxic therapy and HER2 blockade, n (%)</td>
<td>Multi-agent CT and trastuzumab</td>
<td>135 (17.6)</td>
<td>0 (0)</td>
<td>31 (24.4)</td>
<td>0 (0)</td>
<td>67 (42.3)</td>
<td>0 (0)</td>
<td>37 (55.2)</td>
</tr>
<tr>
<td>Cytotoxic therapy and HER2 blockade, n (%)</td>
<td>Multi-agent CT and dual blockade</td>
<td>202 (26.4)</td>
<td>0 (0)</td>
<td>96 (75.6)</td>
<td>0 (0)</td>
<td>88 (56.8)</td>
<td>0 (0)</td>
<td>18 (26.9)</td>
</tr>
<tr>
<td>Dual blockade alone</td>
<td>84 (11.0)</td>
<td>0 (0)</td>
<td>0 (0)</td>
<td>0 (0)</td>
<td>0 (0)</td>
<td>0 (0)</td>
<td>0 (0)</td>
<td>84 (100)</td>
</tr>
</tbody>
</table>

AC-T-DM1-P, doxorubicin, cyclophosphamide, ado-trastuzumab emtansine and pertuzumab; AC-TH, doxorubicin, cyclophosphamide, paclitaxel and trastuzumab; AC-THP, doxorubicin, cyclophosphamide, paclitaxel, trastuzumab and pertuzumab; TCH, docetaxel, carboplatin and trastuzumab; THP, docetaxel, carboplatin, trastuzumab and pertuzumab; TH, paclitaxel and trastuzumab; HL, paclitaxel, trastuzumab and lapatinib; HP, paclitaxel, trastuzumab and pertuzumab.

effect, a patient-level analysis was carried out adjusting by cohort. In all analyses, 57 patients who did not receive neoadjuvant trastuzumab (i.e. the TL arm from CALGB-40601) and 116 tumor samples from NEOHER which were used for building the HER2DX pCR score (i.e. training dataset) were excluded. Across the seven cohorts, pCR was defined as ypT0/isN0.

The second objective was to evaluate the predictive ability of the HER2DX pCR score to identify patients who will achieve pCR to dual HER2 blockade when given with chemotherapy. The third objective was to assess the predictive capacity of HER2DX pCR score to identify patients who benefit from multi-agent chemotherapy in the context of taxane-based therapy and dual HER2 blockade. Interaction tests, adjusted by cohort, were used to evaluate the different effects of treatment according to HER2DX pCR groups. The fourth objective was to explore the biology of the HER2DX pCR groups using HER2+ tumor samples from TCGA breast cancer project. To validate the performance of the HER2DX pCR score, the ROC-AUC, the area under the precision-recall curve and calibration plots were calculated.

Finally, we evaluated the ability of the HER2DX risk score to predict survival outcome according to pCR status. Event-free survival (EFS) and overall survival (OS) were available in 268 patients from the NEOHER and PAMELA cohorts. The Kaplan–Meier method was used to estimate survival outcomes at 6 years. Cox proportional hazards models were used to obtain hazard ratios in (i) the overall population after adjusting by pCR status, (ii) pCR only and (iii) non-pCR only. The median follow-up was calculated using the reverse Kaplan–Meier method. For all statistical analyses, the significance level was set at two-sided alpha of 0.05 and all analyses were carried out using R statistical software version 4.1.2.

RESULTS

Clinicopathological features

Seven hundred sixty-five patients with available pre-treatment baseline HER2DX and clinical data were available across seven cohorts (Supplementary Figure S2, available at https://doi.org/10.1016/j.annonc.2023.05.012). The mean age was 51.6 years (range 22-86 years), clinical T1 disease represented 21.2%, clinical node-positive disease (cN1-3) represented 46.5% and 63.7% of tumors were HR-positive (Table 1). Patients were treated with neoadjuvant trastuzumab in combination with multi-agent chemotherapy (n = 337), a single taxane (n = 344), no chemotherapy (n = 84), pertuzumab (n = 328), lapatinib (n = 187) or without a second anti-HER2 drug (n = 250). The overall pCR rate was...
Figure 1. Association of HER2DX pCR score with pCR in the combined neoadjuvant cohort of 765 patients. (A) Univariable and multivariable logistic models to predict pCR (n = 765). (B) Pooled results in patients treated with chemotherapy and dual HER2 blockade (n = 431), with chemotherapy and trastuzumab (n = 250) or dual HER2 blockade alone (n = 84). (C) Pooled results in patients with HR-positive (n = 486) or HR-negative (n = 277) disease. (D) Calibration plots for the pCR endpoint. X-axis shows average predicted probability values for each decile, and y-axis shows corresponding observed probability in each decile. Error bars represent 95% CIs of mean predicted probabilities. The diagonal line represents the perfect calibration, the dotted curve represents the estimated calibration and the solid curve represents the apparent probability.
49.9% (95% CI 46.3% to 53.5%): 40.7% (36.4%-45.3%) in patients with HR-positive disease, 66.1% (60.1%-71.6%) in patients with HR-negative disease, 46.0% (39.7%-52.4%) in patients treated with chemotherapy and trastuzumab, 29.8% (20.5%-40.9%) in patients treated with dual HER2 blockade in the absence of chemotherapy and 56.1% (51.3%-60.9%) in patients treated with chemotherapy and dual HER2 blockade. Among patients with chemotherapy and dual HER2 blockade (n = 431), the pCR rate with pertuzumab or lapatinib as a second anti-HER2 agent was 56.7% (51.1%-62.1%) and 54.4% (44.3%-64.1%), respectively.

**HER2DX pCR score versus pCR**

In the combined cohort, HER2DX pCR score (as a continuous variable from 0 to 10) was significantly associated with pCR (OR per 10-unit increase = 1.59, 95% CI 1.43-1.77, P < 0.001) after adjusting for treatment and clinicopathological factors (Figure 1A). Similar results were obtained in the sensitivity analysis (Supplementary Table S2, available at https://doi.org/10.1016/j.annonc.2023.05.012). The ability of HER2DX pCR score to predict pCR was confirmed in patients treated with dual HER2 blockade and chemotherapy or trastuzumab and chemotherapy, and within HR-positive and HR-negative disease (Figure 1B and C). Calibration plots comparing predicted and observed probabilities showed a correct calibration performance (Figure 1D). The AUC for HER2DX pCR score was 0.75 (95% CI 0.72-0.79) (Figure 1E, all populations), 0.78 (chemotherapy and dual HER2 blockade), 0.70 (chemotherapy and trastuzumab), 0.75 (HR-positive) and 0.70 (HR-negative) (Supplementary Figure S3, available at https://doi.org/10.1016/j.annonc.2023.05.012). The area under the precision-recall curves was 0.73 for all populations (Supplementary Figure S4, available at https://doi.org/10.1016/j.annonc.2023.05.012).

To better stratify patients in clinical practice, the predefined cut-offs were used to classify patients in HER2DX pCR groups. The proportion of tumors in HER2DX low-, medium- and high-pCR groups was 33.6%, 32.2% and 34.2% in the overall population, 49.8%, 35.4% and 14.8% in the HR-positive population and 5.1%, 26.4% and 68.6% in the HR-negative population, respectively. The pCR rates in the HER2DX pCR-medium and pCR-low groups were 74.0%, 55.3% and 20.2%, respectively (high versus low: OR = 11.25, 95% CI 7.51-17.10, P < 0.001).

**HER2DX pCR score and dual HER2 blockade response**

Among patients who received chemotherapy (n = 681), 431 patients (63.3%) received dual HER2 blockade and 250 (36.7%) received trastuzumab alone. The overall pCR rate in patients treated with and without dual HER2 blockade was 56.1% and 46.0% (i.e. delta of 10.1%, OR = 1.50, 95% CI 1.10-2.06, P = 0.01). This difference in pCR rates is consistent with the known effect of adding lapatinib or pertuzumab to trastuzumab and chemotherapy in other randomized trials such as NeoSphere, NSABP-B41 and NeoALTTO.

The pCR rates with and without dual HER2 blockade differed according to HER2DX pCR score (Figure 2A). In patients with HER2DX pCR-high, -medium and -low disease, the difference in pCR rates with dual blockade versus single anti-HER2 were 17.6%, 5.4% and 4.6% in favor of dual HER2 blockade, respectively. A significant increase in pCR rate due to dual HER2 blockade was found only in HER2DX pCR-high tumors (OR = 2.36, 95% CI 1.09-5.42, P = 0.03) but not in HER2DX pCR-medium or -low tumors (Figure 2B). However, the interaction tests after adjusting by cohort type did not reach statistical significance (HER2DX pCR-high versus others, P = 0.130; HER2DX pCR-high versus pCR-low, P = 0.070).

**HER2DX pCR score and multi-agent chemotherapy response**

Among the 431 patients receiving dual HER2 blockade and chemotherapy, 229 (53.1%) received a single taxane and 202 (46.9%) received multi-agent chemotherapy. The overall pCR rate in patients treated with dual HER2 blockade with and without multi-agent chemotherapy was 58.4% and 54.1%, respectively (i.e. delta of 4.3%, OR = 1.19, 95% CI 0.81-1.74, P = 0.37). The pCR rates with and without multi-agent chemotherapy differed according to HER2DX pCR score. In patients with HER2DX pCR-high, -medium and -low disease, the difference in pCR rates (with multi-agent chemotherapy versus a single taxane) were −4.5%, 25.5% and −3.2%, respectively. A significant increase in pCR rate due to multi-agent chemotherapy was found only in HER2DX pCR-medium tumors (OR = 3.11, 95% CI 1.54-6.49, P = 0.002) but not in HER2DX pCR-high or -low tumors (Figure 2C). A statistically significant interaction was observed between HER2DX pCR-medium group and the other groups after adjusting by cohort type (P = 0.001).

Overall, the value of HER2DX pCR groups to identify patients who benefit from multi-agent chemotherapy and dual HER2 blockade was independent of clinicopathological characteristics (Figures 1A and 3A).

**Biology associated with HER2DX pCR score**

To explore the biological differences among HER2DX pCR groups, we interrogated the HER2DX test as well as genomic
Figure 2. Association of HER2DX pCR groups with response to dual HER2 blockade and with response to multi-agent chemotherapy in the combined neoadjuvant cohort. (A) Bar plots showing the pCR rates across the HER2DX pCR groups based on single versus dual HER2 blockade. (B) Forest plots evaluating the association of HER2DX pCR groups with pCR according to dual HER2 blockade administration in cohorts that compared dual blockade versus single anti-HER2 (DAPHNe, BioHER and PAMELA cohorts were not included). (C) Bar plots showing the pCR rates across the HER2DX pCR groups based on single taxane versus multi-agent chemotherapy in the cohort of 367 patients treated with dual HER2 blockade. 

95% CI, 95% confidence interval; CT, chemotherapy; OR, odds ratio; pCR, pathological complete response.

a indicates statistical significant difference.
and proteomic data from 161 HER2+ tumors of the TCGA breast cancer dataset\(^2\) (Figure 3B). At the DNA level, TP53 somatic mutations were found in 56.0%, 38.0% and 9.3% of HER2DX pCR-high, -medium and -low tumors, respectively \((P < 0.001)\). No statistically significant differences across the HER2DX pCR groups were observed regarding PIK3CA mutations. At the RNA level, 3033 of 12,369 (24.5%) genes were found differentially expressed across the HER2DX pCR groups (false discovery rate <1%). The significant genes generally tracked the four biological processes identified by the HER2DX assay (i.e. luminal differentiation, proliferation, HER2 amplicon and immune). As expected, HER2DX pCR-high tumors showed the highest expression of the HER2 amplicon-related genes, immune genes and proliferation-related genes, and the lowest expression of luminal genes. Finally, we evaluated the protein expression of HER2 and estrogen receptor by reverse-phase protein arrays across the HER2DX pCR groups. Concordant with the gene expression results, HER2DX pCR-high tumors showed the highest and lowest expression of HER2 and ER, respectively (Figure 3B).

**HER2DX risk score beyond pCR status**

To evaluate the ability of HER2DX risk score to identify patients with lower risk of recurrence irrespective of pCR status, survival outcomes were evaluated in 268 patients treated with (neo)adjuvant trastuzumab-based therapy with long-term follow-up (NEOHER and PAMELA cohorts, median follow-up of 6.2 years). In this cohort, pCR status showed a tendency for association with better EFS (hazard ratio = 0.43, 95% CI 0.18-1.02, \(P = 0.06\)) (Figure 4A). The hazard ratio estimate of 0.43 in our study is consistent with previous studies.\(^9,10\) Of note, only 14 (9.3%) patients with residual disease at surgery received adjuvant T-DM1.

To evaluate the clinical utility of the HER2DX risk score, the predefined risk cut-off was used to classify patients in HER2DX low-risk versus high-risk. Among patients who...
achieved a pCR (n = 118), the 6-year EFS for patients with HER2DX low- and high-risk disease was 98.1% and 89.4%, respectively (Figure 4C). Among patients who did not achieve a pCR (n = 150), EFS outcomes were also better for HER2DX low-risk patients compared to HER2DX high-risk patients (EFS at 6 years of 93.5% versus 78.8%) (Figure 4D). In the multivariable analysis, the HER2DX risk group was statistically associated with EFS (low versus high risk, hazard ratio = 0.19, 95% CI 0.07-0.49, P < 0.001) and OS (low versus high risk, hazard ratio = 0.13, 95% CI 0.03-0.56, P = 0.006) after adjusting by pCR (Supplementary Table S3; Supplementary Figure S5, available at https://doi.org/10.1016/j.annonc.2023.05.012).

**DISCUSSION**

We present the largest study to date of the HER2DX as a predictor of pCR following neoadjuvant trastuzumab-based chemotherapy. Specifically, we confirm that the HER2DX pCR score is significantly associated with pCR independent of the type of chemotherapy and anti-HER2 therapy, and HR status. Importantly, we confirm that pCR rates of 80%-90% can be achieved in patients with HER2DX pCR-high disease following a single taxane and dual HER2 blockade. In addition, multi-agent chemotherapy does not seem to increase the pCR rate in HER2DX pCR-low or -high tumors but increases in pCR-medium tumors.

The underlying biological explanation of our observations is that HER2DX pCR-high tumors are the most HER2 addicted, the most proliferative, the most immune infiltrated and the ones with the lowest expression of luminal features. These biological features have been previously linked to response to HER2-directed therapy and chemotherapy sensitivity, even within HER2+/HR-positive disease. On the other extreme, the pCR rates in HER2DX pCR-low disease are ≤30%, whether dual HER2 blockade and/or multi-agent chemotherapy are administered. The underlying biological explanation is that this group of tumors is the least HER2 addicted, the least proliferative and...
the least immune infiltrated, while it has the highest expression of luminal features. These biological features are linked to resistance to anti-HER2 therapy and chemotherapy but linked to sensitivity to endocrine therapy. Finally, the HER2DX pCR-medium group has an intermediate biological state, and multi-agent chemotherapy is particularly active in this group of tumors and increases the pCR rate over a single taxane. Of note, each HER2DX pCR group represents approximately one-third of patients with early-stage HER2+ breast cancer.

Upfront identification of patients with early-stage HER2+ breast cancer who benefit the most from neoadjuvant dual HER2 blockade is needed. Despite the Food and Drug Administration and European Medicines Agency approval of (neo)adjuvant pertuzumab in clinically high-risk HER2+ breast cancer, the absolute increase in pCR rates in unselected patients with stage II-III disease is ≤20%. Similar results are observed in randomized trials with chemotherapy and trastuzumab, with or without lapatinib. In addition, the absolute increase in invasive disease-free survival when 1 year of adjuvant pertuzumab or lapatinib is added to trastuzumab-based chemotherapy is small, except for pertuzumab in node-positive disease in the APHINITY trial (delta of 4.9% at 8 years). Moreover, no OS benefit has been observed in any subgroup in APHINITY.

In the context of early-stage HER2+ breast cancer, an important clinical consideration is determining which patients may be eligible for neoadjuvant therapy and can safely transition from multi-agent chemotherapy to single-agent taxane-based therapy. Neoadjuvant THP is currently not recommended by clinical guidelines, and two ongoing phase II clinical trials are evaluating this approach. The CompassHER2-pCR study (NCT04266249) led by ECOG-ACRIN will treat 2156 patients with stage II-III HER2+ breast cancer (both HR-positive and HR-negative) with 3 months of a single taxane with trastuzumab and pertuzumab. If pCR is achieved, patients do not receive additional chemotherapy and will continue with HP to complete 1 year. The Decrescendo trial (NCT04675827) led by BIG will treat 1065 patients with stage II-III HER2+ breast cancer (both HR-positive and HR-negative) with 3 months of a single taxane with trastuzumab and pertuzumab. If pCR is achieved, patients will not receive additional chemotherapy and will continue with HP to complete 1 year. The primary endpoint of both trials is 3-year recurrence-free survival in patients who achieve a pCR. In this context, HER2DX pCR score would allow an upfront identification of patients most likely to benefit from this treatment approach (i.e. those with HER2DX pCR-high disease), and could help avoid the need for treatment escalation post-operatively by identifying those patients that may need no more than just a single taxane in the preoperative setting.

The de-escalation of systemic therapy may require additional prognostic information beyond pCR status. Our study revealed that the HER2DX risk score provides independent prognostic information that goes beyond pCR status. Consequently, HER2DX risk score may assist in identifying patients with low-risk disease, irrespective of their pCR status or whether they receive adjuvant T-DM1 therapy. These findings are consistent with a recent combined patient-level analysis of five neoadjuvant trials, which found that baseline tumor size and nodal status were associated with survival outcomes in patients with a pCR across subtypes, including HER2+ breast cancer. Additionally, the current results are consistent with previous findings from the CALGB-40601 phase III trial, in which the HER2DX risk score was assessed in silico using genomic signatures only, without considering tumor size or nodal status. In that study, the HER2DX risk score was significantly associated with EFS and OS, independent of pCR status.

Regarding de-escalation of trastuzumab, several non-inferiority randomized studies with over 10 000 patients have shown a small absolute reduction in risk of recurrence and a small absolute increase in risk of cardiac toxicity with 12 months of therapy compared with shorter durations (e.g. 6 months). Although decreasing the duration of adjuvant trastuzumab has not been endorsed by clinical guidelines, HER2DX could help identify patients with very low risk of recurrence and low probability of pCR, who would be ideal candidates for a shorter duration of anti-HER2 therapy. In METABRIC and SCAN-B datasets, HER2DX risk score has shown prognostic value beyond the use of trastuzumab. Thus, further studies could also determine the value of HER2DX to identify patients who might benefit from locoregional therapy without the need for any systemic therapy, including trastuzumab.

Our study has several limitations. Firstly, the retrospective nature of this study. Secondly, the lack of a study which randomized patients to a single taxane versus multi-agent chemotherapy. Thirdly, the lack of long-term survival outcome for most of the cohorts. Finally, the fact that HER2DX was evaluated in silico in the ISPY-2 and CALGB-40601 cohorts.

To conclude, HER2DX test results are associated with the likelihood of pCR following neoadjuvant trastuzumab-based chemotherapy and might help identify patients with stage II-III disease who are candidates for neoadjuvant HP in combination with a single taxane over multi-agent chemotherapy. Independent external validation of HER2DX in CompassHER2-pCR trial is planned.

ACKNOWLEDGEMENTS

We thank the patients and family members who participated in all the cohorts analyzed in this study.

FUNDING

This study was supported by the Hospital General Universitario Gregorio Marañón (Madrid, Spain) and Reveal Genomics (Barcelona, Spain). MM received funding from CIBER and Center of Biomedical Research on Cancer [grant number CIBERONC, group CB16/12/00471]. FB-M received funding from Fundación Científica Asociación Española Contra el Cáncer [grant number Ayudas Investigador AECC.
2021- INVES21943BRAS]. EAM acknowledges support as the Rob and Karen Hale Distinguished Chair in Surgical Oncology. OMS is a SEOM Visiting Fellow 2022.

DISCLOSURE

GV has received speaker’s fee from MSD, Pfizer, GSK and Pierre Fabre, has held an advisory role with AstraZeneca and received consultant fees from Reveal Genomics. CBM received honoraria as speakers’ honoraria from Roche, Novartis, Lilly, MSD and AstraZeneca and GSK and Travel Grant from Roche, Novartis and Pfizer. IE reports speaker fees from Roche, Teva, Novartis, Pfizer, Lily and advisory role from Lilly and AstraZeneca. SLT reports consulting or advisory role fees from AstraZeneca, Novartis, Roche, Pfizer, Pierre Fabre, Lilly, Seagen, Daiichi-Sankyo Europe GmbH, Gilead Sciences, MDS, GlaxoSmithKline, Veracyte and speakers bureau fees from Lilly. AP reports advisory and consulting fees from Roche, Pfizer, Novartis, Amgen, BMS, Puma, Oncolytics Biotech, MSD, Guardant Health, Peptomyc and Lilly, lecture fees from Roche, Pfizer, Novartis, Amgen, BMS, NanoString Technologies and Daiichi Sankyo, institutional financial interests from Boehringer, Novartis, Roche, NanoString, Sysmex Europa GmbH, Medica Scientia Innovation Research, SL, Celgene, Astellas and Pfizer; stockholder and consultant of Reveal Genomics, SL; AP is also listed as an inventor on patent applications for the HER2DX assay. CMP is an equity stockholder and consultant of BioClassifier LLC, and for Reveal Genomics. CMP is also listed as an inventor on patents for the Breast PAM50 assay. JSP is an equity stockholder and consultant for Reveal Genomics and is also listed as an inventor on patent applications for the Breast PAM50 assay. FBM has a patent application EP21383165. LP is listed as an inventor on patent application EP2021/070788. EAM reports compensated service on scientific advisory boards for AstraZeneca, Exact Sciences (formerly Genomic Health), Merck, Roche/Gentech; uncompensated service on steering committees for Bristol Myers Squibb, Lilly, and Roche/Gentech; and institutional research support from Roche/Gentech (via SU2C grant) and Gilead. She receives research funding from Susan Komen for the Cure for which she serves as a Scientific Advisor. She also reports uncompensated participation as a member of the American Society of Clinical Oncology Board of Directors. SMT has served as a consultant for: Novartis, Pfizer, Merck, Lilly, Nektar, NanoString Technologies, AstraZeneca, Puma Biotechnology, Gentech/Roche, Eisai, Sanofi, Bristol Myers Squibb, Seattle Genetics, Odonate Therapeutics, OncoPep, Kyowa Hakko Kirin, Samsung Bioepis, CytomX Therapeutics, Daiichi Sankyo, Athenex, Gilead, Mersana, Certara, Chugai Pharma, Ellipses Pharma, Infinity, 4D Pharma, OncoSec Medical Inc., BeyondSpring Pharmaceuticals, OncXerna, Zymeworks, Zentalis, Blueprint Medicines, Reveal Genomics, ARC Therapeutics; SMT has received institutional research funding from Genentech/Roche, Merck, Exelixis, Pfizer, Lilly, Novartis, Bristol Myers Squibb, Eisai, AstraZeneca, NanoString Technologies, Cyclacel, Nektar, Gilead, Odonate Therapeutics, Sanofi, Seattle Genetics. MMa reports research grants from Puma; consulting/advisory fees from Roche, Novartis, AstraZeneca, Daiichi Sankyo, Seagen, Lilly, Sanofi; speakers’ honoraria from Seagen, Lilly, AstraZeneca, Pfizer, Daiichi Sankyo, Roche; leadership or fiduciary role in other board, society, committee, or advocacy group, paid or unpaid: Chairman, GEICAM Member of Board of Directors, TRIO. AGW receives institutional research funding from Genentech/Roche, Macrogenics and Merck. NMT reports research and consulting from AstraZeneca. MM-Ag reported being an employee of Reveal Genomics. PV reported a patent for EP21383165 issued as well as being a cofounder of Reveal Genomics. SP has served as an advisor/consultant for AstraZeneca, Daiichi Sankyo Eisai, Novartis, Polyphor, Roche, PierreFabre, Pfizer, and SeattleGenetics. VG reports consulting fees and fees for Non-CME services from Amgen, Exact Science, Gilead, GSK, Lilly, Merk Serono, MSD, Pfizer and Sanofi. GG reports fees for invited speaker from Eli Lilly and Novartis, and consulting fees from Gilead. AV reports grants and personal fees from Incyte and has the DNAXD patent filed (EP22382387.3). PC has received speaker’s fee from Roche, Novartis, AstraZeneca, Lilly and BMS, has held an advisory role with Daiichi Sankyo/Lilly, Reveal Genomics and Gilead Sciences, research funding from Merck KGaA and has a HER2DX patent. JC declares consulting/advisory for Roche, Celgene, Celllestia, AstraZeneca, Seattle Genetics, Daiichi Sankyo, Erytech, Athenex, Polyphor, Lilly, Merck Sharp&Dohme, GSK, Leuko, Biosia, Clovis Oncology, Boehringer Ingelheim, Ellipses, HiberCell, Biolnvent, Gemoab, Gilead, Menarini, Zymeworks, Reveal Genomics, Express2ion Biotechnologies; honoraria from Roche, Novartis, Celgene, Eisai, Pfizer, Samsung Bioepis, Lilly, Merck Sharp&Dohme, Daiichi Sankyo; research funding to the institution from Roche, Ariad pharmaceuticals, AstraZeneca, Baxalta GMBH/Servier Affaires, Bayer healthcare, Eisai, F.Hoffman-La Roche, Guardanth health, Merck Sharp&Dohme, Pfizer, Pipir Therapeutics, Puma C, Queen Mary University of London; Stocks in MedSIR, Nektar Pharmaceuticals, Leuko (relative); travel, accommodation, expenses from Roche, Novartis, Eisai, Pfizer, Daiichi Sankyo, AstraZeneca, Gilead; Patents: Pharmaceutical Combinations of a PI3K Inhibitor and a Microtubule Destabilizing Agent. Javier Cortés Castán, Alejandro Piris Giménez, Violeta Serra Elizalde. WO 2014/199294 A. ISSUED Her2 as a predictor of response to dual HER2 blockade in the absence of cytotoxic therapy. Aleix Prat, Antonio Llombart, Javier Cortés. US 2019/0338368 A1. LICENSED. ALC reported being a stockholder of Medsir; receiving grants from Genentech-Roche, Daiichi-Sanyo, Pfizer, and Novartis; and receiving personal fees from Seagen. MV has received honoraria from Daiichi Sankyo, Novartis, Pfizer and Roche; travel grants from Pfizer and Roche; has participated in advisory boards for Novartis and Roche. ADM reports research grant/funding from Pfizer Inc, Novartis, Calithera and Genentech. LC reports uncompensated relationship with Sanofi, G1 Therapeutics, Gentech/Roche, AstraZeneca/Daiichi Sankyo, Apitude Health and Exact Sciences; in addition, Dr. Carey declared that Companies who have provided research funds to her.
institution in the past 1–2 years were Syndax, Immunomedics, Novartis, Nanostring technologies, Abbvie, Seattle Genetics and Veracyte, outside the submitted work. TP fees for Non-CME Services Received Directly from Commercial Interest or their Agents (e.g. speakers’ bureaus); AstraZeneca, Pfizer, Novartis. Consulting Fees (e.g. advisory boards); Novartis. OMS reports travel expenses and consulting fees from Roche and Reveal Genomics and speaker fees from Eisai and Novartis. All other authors have declared no conflicts of interest.

**DATA SHARING**

Deidentified participant data and trial protocol will be made available upon a reasonable request to the corresponding author. Proposals for any purpose will be considered.

**REFERENCES**


